| 查看: 1384 | 回复: 17 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
开发一种新药的惊人花费（The truly staggering cost of inventing new drugs）
|
|||
|
原文链接：http://bioluminor.biomart.cn/news/2770272.htm During the Super Bowl, a representative of the pharmaceutical company Eli Lilly posted the on the company’s corporate blog that the average cost of bringing a new drug to market is $1.3 billion, a price that would buy 371 Super Bowl ads, 16 million official NFL footballs, two pro football stadiums, pay of almost all NFL football players, and every seat in every NFL stadium for six weeks in a row. This is, of course, ludicrous. The average drug developed by a major pharmaceutical company costs at least $4 billion, and it can be as much as $11 billion. The drug industry has been tossing around the $1 billion number for years. It is based largely on a study (supported by drug companies) by Joseph DiMasi of Tufts University. It’s a nice number for the pharmaceutical industry, because it seems to justify the idea that medicines should be pricey (and increasingly, they can be very pricey, costing tens of thousands of dollars per patient per year) without making it seem that inventing new medicines is so expensive an endeavor as to be ultimately futile. But as Bernard Munos of the InnoThink Center for Research In Biomedical Innovation has noted, just adjusting that estimate for current failure rates results in an estimate of $4 billion in research dollars spent for every drug that is approved. But Munos showed me another figure, where he divided each drug company’s R&D budget by the average number of drugs approved. This was far more dramatic. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. Wanting to make this even more rigorous, Forbes (that would be Scott DeCarlo and me) took Munos’ count of drug approvals for the major pharmas and combined it with their research and development spending as reported in annual earnings filings going back fifteen years, pulled from a Thomson Reuters database using FactSet. We adjusted all the figures for inflation. Using both drug approvals and research budgets since 1997 keeps the estimates being skewed by short-term periods when R&D budgets or drug approvals changed dramatically. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. |
回复此楼» 猜你喜欢
药学专硕调剂
已经有0人回复
-
publcif的使用
已经有0人回复
-
药物学论文润色/翻译怎么收费?
已经有62人回复
-
求调剂
已经有2人回复
-
会计专硕求调剂
已经有0人回复
-
新加坡国立大学药学系化学生物学课题组招PhD
已经有14人回复
-
请教酰胺缩合反应
已经有4人回复
-
一志愿大连理工制药工程专硕086002，本科211，总分342
已经有0人回复
-
制药工程专业招收调剂，要求过国家线
已经有0人回复
-
五邑大学药物化学生物学团队-李兰清课题组招收调剂学生
已经有0人回复
» 抢金币啦！回帖就可以得到:
-
94年女征男友
+1/268
-
南方医科大学中药学院 调剂硕士生一名 中药学专业
+1/84
-
北京-89175-事业单位-诚征女友
+1/64
-
长江师范学院 材料与化工专业 招收调剂学生
+1/40
-
沈阳农业大学生物与医药专硕招收调剂生！！！！！！！！！！
+1/37
-
上海大学 “生物有机电子材料及器件”团队硕士、博士研究生招聘
+1/31
-
招聘︱国家纳米科学中心丁宝全杰青团队诚聘博士后（特别研究助理）
+2/30
-
南京林业大学化工院有机合成方向硕士招调剂
+1/14
-
广东唯一石化院校——资源与环境专硕招生
+1/12
-
北京航空航天大学磁粒子成像课题组钟景教授招收2026年秋季“申请考核”博士
+1/8
-
【博士招生】天津理工大学国家杰青王铁课题组招收2026年博士研究生
+1/8
-
南京林业大学化学工程学院柏惺峰课题组诚聘科研助理、水杉英才E类/F类青年教师或博后
+1/7
-
机械求调剂 读研还想学机械
+1/5
-
【博士招生】广东工业大学国家优青课题组招收2026年环境方向博士生
+1/5
-
长江师范学院化学化工学院2026年硕士研究生接收调剂的通知
+1/5
-
福建师范大学国家级人才团队招收2026年博士研究生
+1/4
-
南医大基础医学院招收调剂生（2生信1生物））
+1/3
-
金属材料先进连接技术
+1/3
-
招聘硕博生：基于机器学习和人工智能的结构/合金设计-西安交大
+1/3
-
湘潭大学教师招聘
+1/1
★
小木虫: 金币+0.5, 给个红包，谢谢回帖
小木虫: 金币+0.5, 给个红包，谢谢回帖
|
本帖内容被屏蔽 |
14楼2015-09-17 14:21:15
7楼2015-08-31 16:02:44
9楼2015-09-01 08:14:29
10楼2015-09-01 08:19:15
